Global Latex Allergy

Latex Allergy Comprehensive Study by Type (IgE-mediated allergic reaction (Type I), Allergic contact dermatitis (Type IV), Irritant contact dermatitis), Application (Healthcare workers, Rubber industry, Others), Cause (Direct contact (latex gloves, condoms and balloons.), Inhalation (Latex products, especially gloves, release latex particles)), Diagnosis Type (Skin Test, Allergy Test), Treatment Type (Epinephrine Injection, Allergy Medication), Symptoms (Mild symptoms (Itching, Skin redness, Hives, or rash), More-severe symptoms (Itching, Others)) Players and Region - Global Market Outlook to 2030

Latex Allergy Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Latex Allergy
Latex allergy is a results to specific proteins discovered in natural rubber latex, a product made from the rubber tree. The Latex allergy generally grows after repeated exposure to products holding natural rubber latex. As many things made from natural rubber, including shoe soles, elastic bands, rubber gloves, condoms, baby-bottle nipples, and balloons, there are many possible routes of exposure that may trigger a reaction. Individuals with latex allergies may also have or develop allergic reactions to some fruits, such as kiwi, bananas,s, and others.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The companies are exploring the market by adopting mergers & acquisitions expansions investments new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Latex Allergy market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

GlaxoSmithKline plc. (United Kingdom), Johnson & Johnson Services, Inc. (United States), Merck & Co., Inc. (United States), Nektar(United States), Novartis AG (Switzerland), Sanofi (France), 3MP(United States), Alcon Vision LLC.( Switzerland) and Rocky Mountain Diagnostics (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Par Pharmaceutical (India), Organon Global Inc. (United States), Hikama Pharmaceuticals (United Kingdom) and Others.

Segmentation Overview
AMA Research has segmented the market of Global Latex Allergy market by Type (IgE-mediated allergic reaction (Type I), Allergic contact dermatitis (Type IV) and Irritant contact dermatitis), Application (Healthcare workers, Rubber industry and Others) and Region.



On the basis of geography, the market of Latex Allergy has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Cause, the sub-segment i.e. Direct contact (latex gloves, condoms and balloons.) will boost the Latex Allergy market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Diagnosis Type, the sub-segment i.e. Skin Test will boost the Latex Allergy market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Treatment Type, the sub-segment i.e. Epinephrine Injection will boost the Latex Allergy market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Symptoms, the sub-segment i.e. Mild symptoms (Itching, Skin redness, Hives, or rash) will boost the Latex Allergy market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Increasing demand for gloves by medical professionals and the public at large lead to a resurgence in the use of latex gloves

Market Growth Drivers:
Rising demand for latex allergy market, Increasing use of Natural rubber latex gloves and Increasing use of balloons and condoms

Challenges:
The difficulty in managing latex allergy and Increasing use of nitrile or vinyl gloves

Restraints:
The availability of the large number of products worldwide that contain latex and it’s often very difficult for people with latex allergy to perform everyday tasks and live a full, active life

Opportunities:
The outburst of the covid-19 has boosted the number of cases of latex allergy, to the latex allergy generally develops after repeated exposure to medical and consumer products containing natural rubber latex.

Market Leaders and their expansionary development strategies
In January 2024, GSK plc and Aiolos Bio, Inc., announced that they have entered into an agreement under which GSK will acquire Aiolos, a clinical-stage biopharmaceutical company focused on addressing the unmet treatment needs of patients with certain respiratory and inflammatory conditions, for a USD1 billion upfront payment and up to USD 400 million in certain success-based regulatory milestone payments.
In April 2021,The GlaxoSmithKline Pharmaceuticals (GSK Pharma) stock has underperformed the overall pharma market over the last one year on account of lower sales in the anti-infectives category.


Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Latex Allergy treatment providers, Government Regulatory and Research Organizations and End-Use Industry

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • IgE-mediated allergic reaction (Type I)
  • Allergic contact dermatitis (Type IV)
  • Irritant contact dermatitis
By Application
  • Healthcare workers
  • Rubber industry
  • Others
By Cause
  • Direct contact (latex gloves, condoms and balloons.)
  • Inhalation (Latex products, especially gloves, release latex particles)

By Diagnosis Type
  • Skin Test
  • Allergy Test

By Treatment Type
  • Epinephrine Injection
  • Allergy Medication

By Symptoms
  • Mild symptoms (Itching, Skin redness, Hives, or rash)
  • More-severe symptoms (Itching, Others)

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising demand for latex allergy market
      • 3.2.2. Increasing use of Natural rubber latex gloves
      • 3.2.3. Increasing use of balloons and condoms
    • 3.3. Market Challenges
      • 3.3.1. The difficulty in managing latex allergy
      • 3.3.2. Increasing use of nitrile or vinyl gloves
    • 3.4. Market Trends
      • 3.4.1. Increasing demand for gloves by medical professionals and the public at large lead to a resurgence in the use of latex gloves
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Latex Allergy, by Type, Application, Cause, Diagnosis Type, Treatment Type, Symptoms and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Latex Allergy (Value)
      • 5.2.1. Global Latex Allergy by: Type (Value)
        • 5.2.1.1. IgE-mediated allergic reaction (Type I)
        • 5.2.1.2. Allergic contact dermatitis (Type IV)
        • 5.2.1.3. Irritant contact dermatitis
      • 5.2.2. Global Latex Allergy by: Application (Value)
        • 5.2.2.1. Healthcare workers
        • 5.2.2.2. Rubber industry
        • 5.2.2.3. Others
      • 5.2.3. Global Latex Allergy by: Cause (Value)
        • 5.2.3.1. Direct contact (latex gloves, condoms and balloons.)
        • 5.2.3.2. Inhalation (Latex products, especially gloves, release latex particles)
      • 5.2.4. Global Latex Allergy by: Diagnosis Type (Value)
        • 5.2.4.1. Skin Test
        • 5.2.4.2. Allergy Test
      • 5.2.5. Global Latex Allergy by: Treatment Type (Value)
        • 5.2.5.1. Epinephrine Injection
        • 5.2.5.2. Allergy Medication
      • 5.2.6. Global Latex Allergy by: Symptoms (Value)
        • 5.2.6.1. Mild symptoms (Itching, Skin redness, Hives, or rash)
        • 5.2.6.2. More-severe symptoms (Itching, Others)
      • 5.2.7. Global Latex Allergy Region
        • 5.2.7.1. South America
          • 5.2.7.1.1. Brazil
          • 5.2.7.1.2. Argentina
          • 5.2.7.1.3. Rest of South America
        • 5.2.7.2. Asia Pacific
          • 5.2.7.2.1. China
          • 5.2.7.2.2. Japan
          • 5.2.7.2.3. India
          • 5.2.7.2.4. South Korea
          • 5.2.7.2.5. Taiwan
          • 5.2.7.2.6. Australia
          • 5.2.7.2.7. Rest of Asia-Pacific
        • 5.2.7.3. Europe
          • 5.2.7.3.1. Germany
          • 5.2.7.3.2. France
          • 5.2.7.3.3. Italy
          • 5.2.7.3.4. United Kingdom
          • 5.2.7.3.5. Netherlands
          • 5.2.7.3.6. Rest of Europe
        • 5.2.7.4. MEA
          • 5.2.7.4.1. Middle East
          • 5.2.7.4.2. Africa
        • 5.2.7.5. North America
          • 5.2.7.5.1. United States
          • 5.2.7.5.2. Canada
          • 5.2.7.5.3. Mexico
  • 6. Latex Allergy: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. GlaxoSmithKline plc. (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Johnson & Johnson Services, Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Merck & Co., Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Nektar(United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Novartis AG (Switzerland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Sanofi (France)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. 3MP(United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Alcon Vision LLC.( Switzerland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Rocky Mountain Diagnostics (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Latex Allergy Sale, by Type, Application, Cause, Diagnosis Type, Treatment Type, Symptoms and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Latex Allergy (Value)
      • 7.2.1. Global Latex Allergy by: Type (Value)
        • 7.2.1.1. IgE-mediated allergic reaction (Type I)
        • 7.2.1.2. Allergic contact dermatitis (Type IV)
        • 7.2.1.3. Irritant contact dermatitis
      • 7.2.2. Global Latex Allergy by: Application (Value)
        • 7.2.2.1. Healthcare workers
        • 7.2.2.2. Rubber industry
        • 7.2.2.3. Others
      • 7.2.3. Global Latex Allergy by: Cause (Value)
        • 7.2.3.1. Direct contact (latex gloves, condoms and balloons.)
        • 7.2.3.2. Inhalation (Latex products, especially gloves, release latex particles)
      • 7.2.4. Global Latex Allergy by: Diagnosis Type (Value)
        • 7.2.4.1. Skin Test
        • 7.2.4.2. Allergy Test
      • 7.2.5. Global Latex Allergy by: Treatment Type (Value)
        • 7.2.5.1. Epinephrine Injection
        • 7.2.5.2. Allergy Medication
      • 7.2.6. Global Latex Allergy by: Symptoms (Value)
        • 7.2.6.1. Mild symptoms (Itching, Skin redness, Hives, or rash)
        • 7.2.6.2. More-severe symptoms (Itching, Others)
      • 7.2.7. Global Latex Allergy Region
        • 7.2.7.1. South America
          • 7.2.7.1.1. Brazil
          • 7.2.7.1.2. Argentina
          • 7.2.7.1.3. Rest of South America
        • 7.2.7.2. Asia Pacific
          • 7.2.7.2.1. China
          • 7.2.7.2.2. Japan
          • 7.2.7.2.3. India
          • 7.2.7.2.4. South Korea
          • 7.2.7.2.5. Taiwan
          • 7.2.7.2.6. Australia
          • 7.2.7.2.7. Rest of Asia-Pacific
        • 7.2.7.3. Europe
          • 7.2.7.3.1. Germany
          • 7.2.7.3.2. France
          • 7.2.7.3.3. Italy
          • 7.2.7.3.4. United Kingdom
          • 7.2.7.3.5. Netherlands
          • 7.2.7.3.6. Rest of Europe
        • 7.2.7.4. MEA
          • 7.2.7.4.1. Middle East
          • 7.2.7.4.2. Africa
        • 7.2.7.5. North America
          • 7.2.7.5.1. United States
          • 7.2.7.5.2. Canada
          • 7.2.7.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Latex Allergy: by Type(USD Million)
  • Table 2. Latex Allergy IgE-mediated allergic reaction (Type I) , by Region USD Million (2018-2023)
  • Table 3. Latex Allergy Allergic contact dermatitis (Type IV) , by Region USD Million (2018-2023)
  • Table 4. Latex Allergy Irritant contact dermatitis , by Region USD Million (2018-2023)
  • Table 5. Latex Allergy: by Application(USD Million)
  • Table 6. Latex Allergy Healthcare workers , by Region USD Million (2018-2023)
  • Table 7. Latex Allergy Rubber industry , by Region USD Million (2018-2023)
  • Table 8. Latex Allergy Others , by Region USD Million (2018-2023)
  • Table 9. Latex Allergy: by Cause(USD Million)
  • Table 10. Latex Allergy Direct contact (latex gloves, condoms and balloons.) , by Region USD Million (2018-2023)
  • Table 11. Latex Allergy Inhalation (Latex products, especially gloves, release latex particles) , by Region USD Million (2018-2023)
  • Table 12. Latex Allergy: by Diagnosis Type(USD Million)
  • Table 13. Latex Allergy Skin Test , by Region USD Million (2018-2023)
  • Table 14. Latex Allergy Allergy Test , by Region USD Million (2018-2023)
  • Table 15. Latex Allergy: by Treatment Type(USD Million)
  • Table 16. Latex Allergy Epinephrine Injection , by Region USD Million (2018-2023)
  • Table 17. Latex Allergy Allergy Medication , by Region USD Million (2018-2023)
  • Table 18. Latex Allergy: by Symptoms(USD Million)
  • Table 19. Latex Allergy Mild symptoms (Itching, Skin redness, Hives, or rash) , by Region USD Million (2018-2023)
  • Table 20. Latex Allergy More-severe symptoms (Itching, Others) , by Region USD Million (2018-2023)
  • Table 21. South America Latex Allergy, by Country USD Million (2018-2023)
  • Table 22. South America Latex Allergy, by Type USD Million (2018-2023)
  • Table 23. South America Latex Allergy, by Application USD Million (2018-2023)
  • Table 24. South America Latex Allergy, by Cause USD Million (2018-2023)
  • Table 25. South America Latex Allergy, by Diagnosis Type USD Million (2018-2023)
  • Table 26. South America Latex Allergy, by Treatment Type USD Million (2018-2023)
  • Table 27. South America Latex Allergy, by Symptoms USD Million (2018-2023)
  • Table 28. Brazil Latex Allergy, by Type USD Million (2018-2023)
  • Table 29. Brazil Latex Allergy, by Application USD Million (2018-2023)
  • Table 30. Brazil Latex Allergy, by Cause USD Million (2018-2023)
  • Table 31. Brazil Latex Allergy, by Diagnosis Type USD Million (2018-2023)
  • Table 32. Brazil Latex Allergy, by Treatment Type USD Million (2018-2023)
  • Table 33. Brazil Latex Allergy, by Symptoms USD Million (2018-2023)
  • Table 34. Argentina Latex Allergy, by Type USD Million (2018-2023)
  • Table 35. Argentina Latex Allergy, by Application USD Million (2018-2023)
  • Table 36. Argentina Latex Allergy, by Cause USD Million (2018-2023)
  • Table 37. Argentina Latex Allergy, by Diagnosis Type USD Million (2018-2023)
  • Table 38. Argentina Latex Allergy, by Treatment Type USD Million (2018-2023)
  • Table 39. Argentina Latex Allergy, by Symptoms USD Million (2018-2023)
  • Table 40. Rest of South America Latex Allergy, by Type USD Million (2018-2023)
  • Table 41. Rest of South America Latex Allergy, by Application USD Million (2018-2023)
  • Table 42. Rest of South America Latex Allergy, by Cause USD Million (2018-2023)
  • Table 43. Rest of South America Latex Allergy, by Diagnosis Type USD Million (2018-2023)
  • Table 44. Rest of South America Latex Allergy, by Treatment Type USD Million (2018-2023)
  • Table 45. Rest of South America Latex Allergy, by Symptoms USD Million (2018-2023)
  • Table 46. Asia Pacific Latex Allergy, by Country USD Million (2018-2023)
  • Table 47. Asia Pacific Latex Allergy, by Type USD Million (2018-2023)
  • Table 48. Asia Pacific Latex Allergy, by Application USD Million (2018-2023)
  • Table 49. Asia Pacific Latex Allergy, by Cause USD Million (2018-2023)
  • Table 50. Asia Pacific Latex Allergy, by Diagnosis Type USD Million (2018-2023)
  • Table 51. Asia Pacific Latex Allergy, by Treatment Type USD Million (2018-2023)
  • Table 52. Asia Pacific Latex Allergy, by Symptoms USD Million (2018-2023)
  • Table 53. China Latex Allergy, by Type USD Million (2018-2023)
  • Table 54. China Latex Allergy, by Application USD Million (2018-2023)
  • Table 55. China Latex Allergy, by Cause USD Million (2018-2023)
  • Table 56. China Latex Allergy, by Diagnosis Type USD Million (2018-2023)
  • Table 57. China Latex Allergy, by Treatment Type USD Million (2018-2023)
  • Table 58. China Latex Allergy, by Symptoms USD Million (2018-2023)
  • Table 59. Japan Latex Allergy, by Type USD Million (2018-2023)
  • Table 60. Japan Latex Allergy, by Application USD Million (2018-2023)
  • Table 61. Japan Latex Allergy, by Cause USD Million (2018-2023)
  • Table 62. Japan Latex Allergy, by Diagnosis Type USD Million (2018-2023)
  • Table 63. Japan Latex Allergy, by Treatment Type USD Million (2018-2023)
  • Table 64. Japan Latex Allergy, by Symptoms USD Million (2018-2023)
  • Table 65. India Latex Allergy, by Type USD Million (2018-2023)
  • Table 66. India Latex Allergy, by Application USD Million (2018-2023)
  • Table 67. India Latex Allergy, by Cause USD Million (2018-2023)
  • Table 68. India Latex Allergy, by Diagnosis Type USD Million (2018-2023)
  • Table 69. India Latex Allergy, by Treatment Type USD Million (2018-2023)
  • Table 70. India Latex Allergy, by Symptoms USD Million (2018-2023)
  • Table 71. South Korea Latex Allergy, by Type USD Million (2018-2023)
  • Table 72. South Korea Latex Allergy, by Application USD Million (2018-2023)
  • Table 73. South Korea Latex Allergy, by Cause USD Million (2018-2023)
  • Table 74. South Korea Latex Allergy, by Diagnosis Type USD Million (2018-2023)
  • Table 75. South Korea Latex Allergy, by Treatment Type USD Million (2018-2023)
  • Table 76. South Korea Latex Allergy, by Symptoms USD Million (2018-2023)
  • Table 77. Taiwan Latex Allergy, by Type USD Million (2018-2023)
  • Table 78. Taiwan Latex Allergy, by Application USD Million (2018-2023)
  • Table 79. Taiwan Latex Allergy, by Cause USD Million (2018-2023)
  • Table 80. Taiwan Latex Allergy, by Diagnosis Type USD Million (2018-2023)
  • Table 81. Taiwan Latex Allergy, by Treatment Type USD Million (2018-2023)
  • Table 82. Taiwan Latex Allergy, by Symptoms USD Million (2018-2023)
  • Table 83. Australia Latex Allergy, by Type USD Million (2018-2023)
  • Table 84. Australia Latex Allergy, by Application USD Million (2018-2023)
  • Table 85. Australia Latex Allergy, by Cause USD Million (2018-2023)
  • Table 86. Australia Latex Allergy, by Diagnosis Type USD Million (2018-2023)
  • Table 87. Australia Latex Allergy, by Treatment Type USD Million (2018-2023)
  • Table 88. Australia Latex Allergy, by Symptoms USD Million (2018-2023)
  • Table 89. Rest of Asia-Pacific Latex Allergy, by Type USD Million (2018-2023)
  • Table 90. Rest of Asia-Pacific Latex Allergy, by Application USD Million (2018-2023)
  • Table 91. Rest of Asia-Pacific Latex Allergy, by Cause USD Million (2018-2023)
  • Table 92. Rest of Asia-Pacific Latex Allergy, by Diagnosis Type USD Million (2018-2023)
  • Table 93. Rest of Asia-Pacific Latex Allergy, by Treatment Type USD Million (2018-2023)
  • Table 94. Rest of Asia-Pacific Latex Allergy, by Symptoms USD Million (2018-2023)
  • Table 95. Europe Latex Allergy, by Country USD Million (2018-2023)
  • Table 96. Europe Latex Allergy, by Type USD Million (2018-2023)
  • Table 97. Europe Latex Allergy, by Application USD Million (2018-2023)
  • Table 98. Europe Latex Allergy, by Cause USD Million (2018-2023)
  • Table 99. Europe Latex Allergy, by Diagnosis Type USD Million (2018-2023)
  • Table 100. Europe Latex Allergy, by Treatment Type USD Million (2018-2023)
  • Table 101. Europe Latex Allergy, by Symptoms USD Million (2018-2023)
  • Table 102. Germany Latex Allergy, by Type USD Million (2018-2023)
  • Table 103. Germany Latex Allergy, by Application USD Million (2018-2023)
  • Table 104. Germany Latex Allergy, by Cause USD Million (2018-2023)
  • Table 105. Germany Latex Allergy, by Diagnosis Type USD Million (2018-2023)
  • Table 106. Germany Latex Allergy, by Treatment Type USD Million (2018-2023)
  • Table 107. Germany Latex Allergy, by Symptoms USD Million (2018-2023)
  • Table 108. France Latex Allergy, by Type USD Million (2018-2023)
  • Table 109. France Latex Allergy, by Application USD Million (2018-2023)
  • Table 110. France Latex Allergy, by Cause USD Million (2018-2023)
  • Table 111. France Latex Allergy, by Diagnosis Type USD Million (2018-2023)
  • Table 112. France Latex Allergy, by Treatment Type USD Million (2018-2023)
  • Table 113. France Latex Allergy, by Symptoms USD Million (2018-2023)
  • Table 114. Italy Latex Allergy, by Type USD Million (2018-2023)
  • Table 115. Italy Latex Allergy, by Application USD Million (2018-2023)
  • Table 116. Italy Latex Allergy, by Cause USD Million (2018-2023)
  • Table 117. Italy Latex Allergy, by Diagnosis Type USD Million (2018-2023)
  • Table 118. Italy Latex Allergy, by Treatment Type USD Million (2018-2023)
  • Table 119. Italy Latex Allergy, by Symptoms USD Million (2018-2023)
  • Table 120. United Kingdom Latex Allergy, by Type USD Million (2018-2023)
  • Table 121. United Kingdom Latex Allergy, by Application USD Million (2018-2023)
  • Table 122. United Kingdom Latex Allergy, by Cause USD Million (2018-2023)
  • Table 123. United Kingdom Latex Allergy, by Diagnosis Type USD Million (2018-2023)
  • Table 124. United Kingdom Latex Allergy, by Treatment Type USD Million (2018-2023)
  • Table 125. United Kingdom Latex Allergy, by Symptoms USD Million (2018-2023)
  • Table 126. Netherlands Latex Allergy, by Type USD Million (2018-2023)
  • Table 127. Netherlands Latex Allergy, by Application USD Million (2018-2023)
  • Table 128. Netherlands Latex Allergy, by Cause USD Million (2018-2023)
  • Table 129. Netherlands Latex Allergy, by Diagnosis Type USD Million (2018-2023)
  • Table 130. Netherlands Latex Allergy, by Treatment Type USD Million (2018-2023)
  • Table 131. Netherlands Latex Allergy, by Symptoms USD Million (2018-2023)
  • Table 132. Rest of Europe Latex Allergy, by Type USD Million (2018-2023)
  • Table 133. Rest of Europe Latex Allergy, by Application USD Million (2018-2023)
  • Table 134. Rest of Europe Latex Allergy, by Cause USD Million (2018-2023)
  • Table 135. Rest of Europe Latex Allergy, by Diagnosis Type USD Million (2018-2023)
  • Table 136. Rest of Europe Latex Allergy, by Treatment Type USD Million (2018-2023)
  • Table 137. Rest of Europe Latex Allergy, by Symptoms USD Million (2018-2023)
  • Table 138. MEA Latex Allergy, by Country USD Million (2018-2023)
  • Table 139. MEA Latex Allergy, by Type USD Million (2018-2023)
  • Table 140. MEA Latex Allergy, by Application USD Million (2018-2023)
  • Table 141. MEA Latex Allergy, by Cause USD Million (2018-2023)
  • Table 142. MEA Latex Allergy, by Diagnosis Type USD Million (2018-2023)
  • Table 143. MEA Latex Allergy, by Treatment Type USD Million (2018-2023)
  • Table 144. MEA Latex Allergy, by Symptoms USD Million (2018-2023)
  • Table 145. Middle East Latex Allergy, by Type USD Million (2018-2023)
  • Table 146. Middle East Latex Allergy, by Application USD Million (2018-2023)
  • Table 147. Middle East Latex Allergy, by Cause USD Million (2018-2023)
  • Table 148. Middle East Latex Allergy, by Diagnosis Type USD Million (2018-2023)
  • Table 149. Middle East Latex Allergy, by Treatment Type USD Million (2018-2023)
  • Table 150. Middle East Latex Allergy, by Symptoms USD Million (2018-2023)
  • Table 151. Africa Latex Allergy, by Type USD Million (2018-2023)
  • Table 152. Africa Latex Allergy, by Application USD Million (2018-2023)
  • Table 153. Africa Latex Allergy, by Cause USD Million (2018-2023)
  • Table 154. Africa Latex Allergy, by Diagnosis Type USD Million (2018-2023)
  • Table 155. Africa Latex Allergy, by Treatment Type USD Million (2018-2023)
  • Table 156. Africa Latex Allergy, by Symptoms USD Million (2018-2023)
  • Table 157. North America Latex Allergy, by Country USD Million (2018-2023)
  • Table 158. North America Latex Allergy, by Type USD Million (2018-2023)
  • Table 159. North America Latex Allergy, by Application USD Million (2018-2023)
  • Table 160. North America Latex Allergy, by Cause USD Million (2018-2023)
  • Table 161. North America Latex Allergy, by Diagnosis Type USD Million (2018-2023)
  • Table 162. North America Latex Allergy, by Treatment Type USD Million (2018-2023)
  • Table 163. North America Latex Allergy, by Symptoms USD Million (2018-2023)
  • Table 164. United States Latex Allergy, by Type USD Million (2018-2023)
  • Table 165. United States Latex Allergy, by Application USD Million (2018-2023)
  • Table 166. United States Latex Allergy, by Cause USD Million (2018-2023)
  • Table 167. United States Latex Allergy, by Diagnosis Type USD Million (2018-2023)
  • Table 168. United States Latex Allergy, by Treatment Type USD Million (2018-2023)
  • Table 169. United States Latex Allergy, by Symptoms USD Million (2018-2023)
  • Table 170. Canada Latex Allergy, by Type USD Million (2018-2023)
  • Table 171. Canada Latex Allergy, by Application USD Million (2018-2023)
  • Table 172. Canada Latex Allergy, by Cause USD Million (2018-2023)
  • Table 173. Canada Latex Allergy, by Diagnosis Type USD Million (2018-2023)
  • Table 174. Canada Latex Allergy, by Treatment Type USD Million (2018-2023)
  • Table 175. Canada Latex Allergy, by Symptoms USD Million (2018-2023)
  • Table 176. Mexico Latex Allergy, by Type USD Million (2018-2023)
  • Table 177. Mexico Latex Allergy, by Application USD Million (2018-2023)
  • Table 178. Mexico Latex Allergy, by Cause USD Million (2018-2023)
  • Table 179. Mexico Latex Allergy, by Diagnosis Type USD Million (2018-2023)
  • Table 180. Mexico Latex Allergy, by Treatment Type USD Million (2018-2023)
  • Table 181. Mexico Latex Allergy, by Symptoms USD Million (2018-2023)
  • Table 182. Company Basic Information, Sales Area and Its Competitors
  • Table 183. Company Basic Information, Sales Area and Its Competitors
  • Table 184. Company Basic Information, Sales Area and Its Competitors
  • Table 185. Company Basic Information, Sales Area and Its Competitors
  • Table 186. Company Basic Information, Sales Area and Its Competitors
  • Table 187. Company Basic Information, Sales Area and Its Competitors
  • Table 188. Company Basic Information, Sales Area and Its Competitors
  • Table 189. Company Basic Information, Sales Area and Its Competitors
  • Table 190. Company Basic Information, Sales Area and Its Competitors
  • Table 191. Latex Allergy: by Type(USD Million)
  • Table 192. Latex Allergy IgE-mediated allergic reaction (Type I) , by Region USD Million (2025-2030)
  • Table 193. Latex Allergy Allergic contact dermatitis (Type IV) , by Region USD Million (2025-2030)
  • Table 194. Latex Allergy Irritant contact dermatitis , by Region USD Million (2025-2030)
  • Table 195. Latex Allergy: by Application(USD Million)
  • Table 196. Latex Allergy Healthcare workers , by Region USD Million (2025-2030)
  • Table 197. Latex Allergy Rubber industry , by Region USD Million (2025-2030)
  • Table 198. Latex Allergy Others , by Region USD Million (2025-2030)
  • Table 199. Latex Allergy: by Cause(USD Million)
  • Table 200. Latex Allergy Direct contact (latex gloves, condoms and balloons.) , by Region USD Million (2025-2030)
  • Table 201. Latex Allergy Inhalation (Latex products, especially gloves, release latex particles) , by Region USD Million (2025-2030)
  • Table 202. Latex Allergy: by Diagnosis Type(USD Million)
  • Table 203. Latex Allergy Skin Test , by Region USD Million (2025-2030)
  • Table 204. Latex Allergy Allergy Test , by Region USD Million (2025-2030)
  • Table 205. Latex Allergy: by Treatment Type(USD Million)
  • Table 206. Latex Allergy Epinephrine Injection , by Region USD Million (2025-2030)
  • Table 207. Latex Allergy Allergy Medication , by Region USD Million (2025-2030)
  • Table 208. Latex Allergy: by Symptoms(USD Million)
  • Table 209. Latex Allergy Mild symptoms (Itching, Skin redness, Hives, or rash) , by Region USD Million (2025-2030)
  • Table 210. Latex Allergy More-severe symptoms (Itching, Others) , by Region USD Million (2025-2030)
  • Table 211. South America Latex Allergy, by Country USD Million (2025-2030)
  • Table 212. South America Latex Allergy, by Type USD Million (2025-2030)
  • Table 213. South America Latex Allergy, by Application USD Million (2025-2030)
  • Table 214. South America Latex Allergy, by Cause USD Million (2025-2030)
  • Table 215. South America Latex Allergy, by Diagnosis Type USD Million (2025-2030)
  • Table 216. South America Latex Allergy, by Treatment Type USD Million (2025-2030)
  • Table 217. South America Latex Allergy, by Symptoms USD Million (2025-2030)
  • Table 218. Brazil Latex Allergy, by Type USD Million (2025-2030)
  • Table 219. Brazil Latex Allergy, by Application USD Million (2025-2030)
  • Table 220. Brazil Latex Allergy, by Cause USD Million (2025-2030)
  • Table 221. Brazil Latex Allergy, by Diagnosis Type USD Million (2025-2030)
  • Table 222. Brazil Latex Allergy, by Treatment Type USD Million (2025-2030)
  • Table 223. Brazil Latex Allergy, by Symptoms USD Million (2025-2030)
  • Table 224. Argentina Latex Allergy, by Type USD Million (2025-2030)
  • Table 225. Argentina Latex Allergy, by Application USD Million (2025-2030)
  • Table 226. Argentina Latex Allergy, by Cause USD Million (2025-2030)
  • Table 227. Argentina Latex Allergy, by Diagnosis Type USD Million (2025-2030)
  • Table 228. Argentina Latex Allergy, by Treatment Type USD Million (2025-2030)
  • Table 229. Argentina Latex Allergy, by Symptoms USD Million (2025-2030)
  • Table 230. Rest of South America Latex Allergy, by Type USD Million (2025-2030)
  • Table 231. Rest of South America Latex Allergy, by Application USD Million (2025-2030)
  • Table 232. Rest of South America Latex Allergy, by Cause USD Million (2025-2030)
  • Table 233. Rest of South America Latex Allergy, by Diagnosis Type USD Million (2025-2030)
  • Table 234. Rest of South America Latex Allergy, by Treatment Type USD Million (2025-2030)
  • Table 235. Rest of South America Latex Allergy, by Symptoms USD Million (2025-2030)
  • Table 236. Asia Pacific Latex Allergy, by Country USD Million (2025-2030)
  • Table 237. Asia Pacific Latex Allergy, by Type USD Million (2025-2030)
  • Table 238. Asia Pacific Latex Allergy, by Application USD Million (2025-2030)
  • Table 239. Asia Pacific Latex Allergy, by Cause USD Million (2025-2030)
  • Table 240. Asia Pacific Latex Allergy, by Diagnosis Type USD Million (2025-2030)
  • Table 241. Asia Pacific Latex Allergy, by Treatment Type USD Million (2025-2030)
  • Table 242. Asia Pacific Latex Allergy, by Symptoms USD Million (2025-2030)
  • Table 243. China Latex Allergy, by Type USD Million (2025-2030)
  • Table 244. China Latex Allergy, by Application USD Million (2025-2030)
  • Table 245. China Latex Allergy, by Cause USD Million (2025-2030)
  • Table 246. China Latex Allergy, by Diagnosis Type USD Million (2025-2030)
  • Table 247. China Latex Allergy, by Treatment Type USD Million (2025-2030)
  • Table 248. China Latex Allergy, by Symptoms USD Million (2025-2030)
  • Table 249. Japan Latex Allergy, by Type USD Million (2025-2030)
  • Table 250. Japan Latex Allergy, by Application USD Million (2025-2030)
  • Table 251. Japan Latex Allergy, by Cause USD Million (2025-2030)
  • Table 252. Japan Latex Allergy, by Diagnosis Type USD Million (2025-2030)
  • Table 253. Japan Latex Allergy, by Treatment Type USD Million (2025-2030)
  • Table 254. Japan Latex Allergy, by Symptoms USD Million (2025-2030)
  • Table 255. India Latex Allergy, by Type USD Million (2025-2030)
  • Table 256. India Latex Allergy, by Application USD Million (2025-2030)
  • Table 257. India Latex Allergy, by Cause USD Million (2025-2030)
  • Table 258. India Latex Allergy, by Diagnosis Type USD Million (2025-2030)
  • Table 259. India Latex Allergy, by Treatment Type USD Million (2025-2030)
  • Table 260. India Latex Allergy, by Symptoms USD Million (2025-2030)
  • Table 261. South Korea Latex Allergy, by Type USD Million (2025-2030)
  • Table 262. South Korea Latex Allergy, by Application USD Million (2025-2030)
  • Table 263. South Korea Latex Allergy, by Cause USD Million (2025-2030)
  • Table 264. South Korea Latex Allergy, by Diagnosis Type USD Million (2025-2030)
  • Table 265. South Korea Latex Allergy, by Treatment Type USD Million (2025-2030)
  • Table 266. South Korea Latex Allergy, by Symptoms USD Million (2025-2030)
  • Table 267. Taiwan Latex Allergy, by Type USD Million (2025-2030)
  • Table 268. Taiwan Latex Allergy, by Application USD Million (2025-2030)
  • Table 269. Taiwan Latex Allergy, by Cause USD Million (2025-2030)
  • Table 270. Taiwan Latex Allergy, by Diagnosis Type USD Million (2025-2030)
  • Table 271. Taiwan Latex Allergy, by Treatment Type USD Million (2025-2030)
  • Table 272. Taiwan Latex Allergy, by Symptoms USD Million (2025-2030)
  • Table 273. Australia Latex Allergy, by Type USD Million (2025-2030)
  • Table 274. Australia Latex Allergy, by Application USD Million (2025-2030)
  • Table 275. Australia Latex Allergy, by Cause USD Million (2025-2030)
  • Table 276. Australia Latex Allergy, by Diagnosis Type USD Million (2025-2030)
  • Table 277. Australia Latex Allergy, by Treatment Type USD Million (2025-2030)
  • Table 278. Australia Latex Allergy, by Symptoms USD Million (2025-2030)
  • Table 279. Rest of Asia-Pacific Latex Allergy, by Type USD Million (2025-2030)
  • Table 280. Rest of Asia-Pacific Latex Allergy, by Application USD Million (2025-2030)
  • Table 281. Rest of Asia-Pacific Latex Allergy, by Cause USD Million (2025-2030)
  • Table 282. Rest of Asia-Pacific Latex Allergy, by Diagnosis Type USD Million (2025-2030)
  • Table 283. Rest of Asia-Pacific Latex Allergy, by Treatment Type USD Million (2025-2030)
  • Table 284. Rest of Asia-Pacific Latex Allergy, by Symptoms USD Million (2025-2030)
  • Table 285. Europe Latex Allergy, by Country USD Million (2025-2030)
  • Table 286. Europe Latex Allergy, by Type USD Million (2025-2030)
  • Table 287. Europe Latex Allergy, by Application USD Million (2025-2030)
  • Table 288. Europe Latex Allergy, by Cause USD Million (2025-2030)
  • Table 289. Europe Latex Allergy, by Diagnosis Type USD Million (2025-2030)
  • Table 290. Europe Latex Allergy, by Treatment Type USD Million (2025-2030)
  • Table 291. Europe Latex Allergy, by Symptoms USD Million (2025-2030)
  • Table 292. Germany Latex Allergy, by Type USD Million (2025-2030)
  • Table 293. Germany Latex Allergy, by Application USD Million (2025-2030)
  • Table 294. Germany Latex Allergy, by Cause USD Million (2025-2030)
  • Table 295. Germany Latex Allergy, by Diagnosis Type USD Million (2025-2030)
  • Table 296. Germany Latex Allergy, by Treatment Type USD Million (2025-2030)
  • Table 297. Germany Latex Allergy, by Symptoms USD Million (2025-2030)
  • Table 298. France Latex Allergy, by Type USD Million (2025-2030)
  • Table 299. France Latex Allergy, by Application USD Million (2025-2030)
  • Table 300. France Latex Allergy, by Cause USD Million (2025-2030)
  • Table 301. France Latex Allergy, by Diagnosis Type USD Million (2025-2030)
  • Table 302. France Latex Allergy, by Treatment Type USD Million (2025-2030)
  • Table 303. France Latex Allergy, by Symptoms USD Million (2025-2030)
  • Table 304. Italy Latex Allergy, by Type USD Million (2025-2030)
  • Table 305. Italy Latex Allergy, by Application USD Million (2025-2030)
  • Table 306. Italy Latex Allergy, by Cause USD Million (2025-2030)
  • Table 307. Italy Latex Allergy, by Diagnosis Type USD Million (2025-2030)
  • Table 308. Italy Latex Allergy, by Treatment Type USD Million (2025-2030)
  • Table 309. Italy Latex Allergy, by Symptoms USD Million (2025-2030)
  • Table 310. United Kingdom Latex Allergy, by Type USD Million (2025-2030)
  • Table 311. United Kingdom Latex Allergy, by Application USD Million (2025-2030)
  • Table 312. United Kingdom Latex Allergy, by Cause USD Million (2025-2030)
  • Table 313. United Kingdom Latex Allergy, by Diagnosis Type USD Million (2025-2030)
  • Table 314. United Kingdom Latex Allergy, by Treatment Type USD Million (2025-2030)
  • Table 315. United Kingdom Latex Allergy, by Symptoms USD Million (2025-2030)
  • Table 316. Netherlands Latex Allergy, by Type USD Million (2025-2030)
  • Table 317. Netherlands Latex Allergy, by Application USD Million (2025-2030)
  • Table 318. Netherlands Latex Allergy, by Cause USD Million (2025-2030)
  • Table 319. Netherlands Latex Allergy, by Diagnosis Type USD Million (2025-2030)
  • Table 320. Netherlands Latex Allergy, by Treatment Type USD Million (2025-2030)
  • Table 321. Netherlands Latex Allergy, by Symptoms USD Million (2025-2030)
  • Table 322. Rest of Europe Latex Allergy, by Type USD Million (2025-2030)
  • Table 323. Rest of Europe Latex Allergy, by Application USD Million (2025-2030)
  • Table 324. Rest of Europe Latex Allergy, by Cause USD Million (2025-2030)
  • Table 325. Rest of Europe Latex Allergy, by Diagnosis Type USD Million (2025-2030)
  • Table 326. Rest of Europe Latex Allergy, by Treatment Type USD Million (2025-2030)
  • Table 327. Rest of Europe Latex Allergy, by Symptoms USD Million (2025-2030)
  • Table 328. MEA Latex Allergy, by Country USD Million (2025-2030)
  • Table 329. MEA Latex Allergy, by Type USD Million (2025-2030)
  • Table 330. MEA Latex Allergy, by Application USD Million (2025-2030)
  • Table 331. MEA Latex Allergy, by Cause USD Million (2025-2030)
  • Table 332. MEA Latex Allergy, by Diagnosis Type USD Million (2025-2030)
  • Table 333. MEA Latex Allergy, by Treatment Type USD Million (2025-2030)
  • Table 334. MEA Latex Allergy, by Symptoms USD Million (2025-2030)
  • Table 335. Middle East Latex Allergy, by Type USD Million (2025-2030)
  • Table 336. Middle East Latex Allergy, by Application USD Million (2025-2030)
  • Table 337. Middle East Latex Allergy, by Cause USD Million (2025-2030)
  • Table 338. Middle East Latex Allergy, by Diagnosis Type USD Million (2025-2030)
  • Table 339. Middle East Latex Allergy, by Treatment Type USD Million (2025-2030)
  • Table 340. Middle East Latex Allergy, by Symptoms USD Million (2025-2030)
  • Table 341. Africa Latex Allergy, by Type USD Million (2025-2030)
  • Table 342. Africa Latex Allergy, by Application USD Million (2025-2030)
  • Table 343. Africa Latex Allergy, by Cause USD Million (2025-2030)
  • Table 344. Africa Latex Allergy, by Diagnosis Type USD Million (2025-2030)
  • Table 345. Africa Latex Allergy, by Treatment Type USD Million (2025-2030)
  • Table 346. Africa Latex Allergy, by Symptoms USD Million (2025-2030)
  • Table 347. North America Latex Allergy, by Country USD Million (2025-2030)
  • Table 348. North America Latex Allergy, by Type USD Million (2025-2030)
  • Table 349. North America Latex Allergy, by Application USD Million (2025-2030)
  • Table 350. North America Latex Allergy, by Cause USD Million (2025-2030)
  • Table 351. North America Latex Allergy, by Diagnosis Type USD Million (2025-2030)
  • Table 352. North America Latex Allergy, by Treatment Type USD Million (2025-2030)
  • Table 353. North America Latex Allergy, by Symptoms USD Million (2025-2030)
  • Table 354. United States Latex Allergy, by Type USD Million (2025-2030)
  • Table 355. United States Latex Allergy, by Application USD Million (2025-2030)
  • Table 356. United States Latex Allergy, by Cause USD Million (2025-2030)
  • Table 357. United States Latex Allergy, by Diagnosis Type USD Million (2025-2030)
  • Table 358. United States Latex Allergy, by Treatment Type USD Million (2025-2030)
  • Table 359. United States Latex Allergy, by Symptoms USD Million (2025-2030)
  • Table 360. Canada Latex Allergy, by Type USD Million (2025-2030)
  • Table 361. Canada Latex Allergy, by Application USD Million (2025-2030)
  • Table 362. Canada Latex Allergy, by Cause USD Million (2025-2030)
  • Table 363. Canada Latex Allergy, by Diagnosis Type USD Million (2025-2030)
  • Table 364. Canada Latex Allergy, by Treatment Type USD Million (2025-2030)
  • Table 365. Canada Latex Allergy, by Symptoms USD Million (2025-2030)
  • Table 366. Mexico Latex Allergy, by Type USD Million (2025-2030)
  • Table 367. Mexico Latex Allergy, by Application USD Million (2025-2030)
  • Table 368. Mexico Latex Allergy, by Cause USD Million (2025-2030)
  • Table 369. Mexico Latex Allergy, by Diagnosis Type USD Million (2025-2030)
  • Table 370. Mexico Latex Allergy, by Treatment Type USD Million (2025-2030)
  • Table 371. Mexico Latex Allergy, by Symptoms USD Million (2025-2030)
  • Table 372. Research Programs/Design for This Report
  • Table 373. Key Data Information from Secondary Sources
  • Table 374. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Latex Allergy: by Type USD Million (2018-2023)
  • Figure 5. Global Latex Allergy: by Application USD Million (2018-2023)
  • Figure 6. Global Latex Allergy: by Cause USD Million (2018-2023)
  • Figure 7. Global Latex Allergy: by Diagnosis Type USD Million (2018-2023)
  • Figure 8. Global Latex Allergy: by Treatment Type USD Million (2018-2023)
  • Figure 9. Global Latex Allergy: by Symptoms USD Million (2018-2023)
  • Figure 10. South America Latex Allergy Share (%), by Country
  • Figure 11. Asia Pacific Latex Allergy Share (%), by Country
  • Figure 12. Europe Latex Allergy Share (%), by Country
  • Figure 13. MEA Latex Allergy Share (%), by Country
  • Figure 14. North America Latex Allergy Share (%), by Country
  • Figure 15. Global Latex Allergy share by Players 2023 (%)
  • Figure 16. Global Latex Allergy share by Players (Top 3) 2023(%)
  • Figure 17. Global Latex Allergy share by Players (Top 5) 2023(%)
  • Figure 18. BCG Matrix for key Companies
  • Figure 19. GlaxoSmithKline plc. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 20. GlaxoSmithKline plc. (United Kingdom) Revenue: by Geography 2023
  • Figure 21. Johnson & Johnson Services, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 22. Johnson & Johnson Services, Inc. (United States) Revenue: by Geography 2023
  • Figure 23. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 24. Merck & Co., Inc. (United States) Revenue: by Geography 2023
  • Figure 25. Nektar(United States) Revenue, Net Income and Gross profit
  • Figure 26. Nektar(United States) Revenue: by Geography 2023
  • Figure 27. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 28. Novartis AG (Switzerland) Revenue: by Geography 2023
  • Figure 29. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 30. Sanofi (France) Revenue: by Geography 2023
  • Figure 31. 3MP(United States) Revenue, Net Income and Gross profit
  • Figure 32. 3MP(United States) Revenue: by Geography 2023
  • Figure 33. Alcon Vision LLC.( Switzerland) Revenue, Net Income and Gross profit
  • Figure 34. Alcon Vision LLC.( Switzerland) Revenue: by Geography 2023
  • Figure 35. Rocky Mountain Diagnostics (United States) Revenue, Net Income and Gross profit
  • Figure 36. Rocky Mountain Diagnostics (United States) Revenue: by Geography 2023
  • Figure 37. Global Latex Allergy: by Type USD Million (2025-2030)
  • Figure 38. Global Latex Allergy: by Application USD Million (2025-2030)
  • Figure 39. Global Latex Allergy: by Cause USD Million (2025-2030)
  • Figure 40. Global Latex Allergy: by Diagnosis Type USD Million (2025-2030)
  • Figure 41. Global Latex Allergy: by Treatment Type USD Million (2025-2030)
  • Figure 42. Global Latex Allergy: by Symptoms USD Million (2025-2030)
  • Figure 43. South America Latex Allergy Share (%), by Country
  • Figure 44. Asia Pacific Latex Allergy Share (%), by Country
  • Figure 45. Europe Latex Allergy Share (%), by Country
  • Figure 46. MEA Latex Allergy Share (%), by Country
  • Figure 47. North America Latex Allergy Share (%), by Country
List of companies from research coverage that are profiled in the study
  • GlaxoSmithKline plc. (United Kingdom)
  • Johnson & Johnson Services, Inc. (United States)
  • Merck & Co., Inc. (United States)
  • Nektar(United States)
  • Novartis AG (Switzerland)
  • Sanofi (France)
  • 3MP(United States)
  • Alcon Vision LLC.( Switzerland)
  • Rocky Mountain Diagnostics (United States)
Additional players considered in the study are as follows:
Par Pharmaceutical (India) , Organon Global Inc. (United States) , Hikama Pharmaceuticals (United Kingdom) , Others
Select User Access Type

Key Highlights of Report


Mar 2024 237 Pages 53 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Latex Allergy Quantitative research analysis
Global Latex Allergy Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as GlaxoSmithKline plc. (United Kingdom), Johnson & Johnson Services, Inc. (United States), Merck & Co., Inc. (United States), Nektar(United States), Novartis AG (Switzerland), Sanofi (France), 3MP(United States), Alcon Vision LLC.( Switzerland) and Rocky Mountain Diagnostics (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Increasing demand for gloves by medical professionals and the public at large lead to a resurgence in the use of latex gloves" is seen as one of major influencing trends for Latex Allergy Market during projected period 2023-2030.
The Latex Allergy market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Latex Allergy Report?

Have a Query? Click Here

Other Related Reports

Maternal Health Comprehensive Study by Type (Hormones, Nutritive, Analgesics, Anti-Infectives, Others), Application (General Health, Bone & Joint Health, Gastrointestinal Health, Immunity, Energy & W...
$ 3650
Metabolic Cart Comprehensive Study by Type (The Breath-By-Breath System, The Mixing Chamber System), Application (Hospital, Private Clinic, Nursing Home, Others), Product (Desktop Device Type, Ground...
$ 3500
Biologics Drug Development Comprehensive Study by Type (Clinical Manufacturing, Formulation Development, Bioassay Development, Analytical Services), Application (In-House, Outsource, Pharma Excess) P...
$ 3500
Apron Racks Comprehensive Study by Type (Wall-Mounted, Mobile), Application (Hospitals, Clinics, Industry, Research Labs, Others), Distribution Channel (OEM, Company Supplier, Retailer, Others) Playe...
$ 3500
Reciprocating Gait Orthosis Comprehensive Study by Type (Horizontal Cable RGO, Rocker Bar RGO, Isocentric RGO), Application (Spinal Cord Injury, Paraplegia, Others), End User (Children's, Teenagers, ...
$ 3500
Heat Therapy Lamp Comprehensive Study by Type (Table, Floor-standing, Wall-mounted), Application (Musculoskeletal Disorder, Sports Medicine, Post Operative Therapy, Mastitis, Chronic Pain Management,...
$ 3650